Famotidine
Teva's generic equivalent to J&J/Merck's Pepcid AC was approved to carry both heartburn prevention and treatment claims, while Ivax' famotidine 10 mg may only carry prevention claim. A brief in "The Tan Sheet" July 30 incorrectly reported Ivax was the first private labeler approved to carry a prevention claim. According to FDA's Office of Generic Drugs, Teva (which licenses its product to Perrigo) challenged both indications covered by a specific patent, while Ivax challenged a separate prevention indication that was not patent-protected. As a result, Teva's famotidine carries six months of generic exclusivity while Ivax' product does not
Learn what's happening at the US FDA. On the go.
More from Archive
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.